Word

VERITAS IN SILICO

Status

Registered

Status Code

700

Status Date

Tuesday, September 20, 2022

Serial Number

79295799

Registration Number

6848721

Registration Date

Tuesday, September 20, 2022

Mark Type

4000

Filing Date

Friday, June 5, 2020

Published for Opposition

Tuesday, April 5, 2022

Trademark Owner History

Veritas In Silico Inc. - Original Registrant

Classifications

41 Educational and instruction services, namely, organizing events for educational and teaching purposes relating to arts, crafts, sports and general knowledge; teaching in the field of drug discovery and development; educating at universities and graduate schools; arranging, conducting and organization of seminars; arranging, conducting and organization of symposiums, lecture meetings, workshops and study groups; arranging, conducting and organization of educational seminars, symposiums, lecture meetings, workshops and study groups in the field of drug discovery and development; providing online non-downloadable electronic publications in the nature of magazines, newsletters, journals and books in the field of nucleic acids, pharmaceuticals, drug discovery and development, medicine, chemicals and engineering; reference libraries of literature and documentary records; book rental; providing online music, sound recordings, videos featuring information and instruction on nucleic acids, pharmaceuticals, drug discovery and development, medicine, chemicals and engineering, images and character text information, non-downloadable; educational services in the nature of providing exhibits of academic materials in the field of nucleic acids, pharmaceuticals, drug discovery and development, medicine, chemicals and engineering; art exhibitions; publication of books; movie theatre presentations, namely, movie showing and movie film production and distribution; production of videotape film in the field of education, culture, entertainment or sports, not for movies or television programs and not for advertising or publicity

40 Custom manufacturing of pharmaceuticals for others; custom synthesis in the nature of custom manufacturing of nucleic acids for others for use in medicines and pharmaceutical preparations; custom extraction, purification, and synthesis, namely, custom manufacturing of pharmaceuticals for others by utilizing genome editing or gene editing technology; custom synthesis in the nature of custom manufacturing of chemical compounds for others for use in medicines and pharmaceutical preparations; custom synthesis in the nature of custom manufacturing of chemical compounds for others; providing material treatment information; printing

5 Pharmaceutical preparations targeting messenger RNA or other types of RNA for the treatment of autoimmune, autoinflammatory diseases, bacterial infections, behavioral and mental disorders, blood diseases, chromosome disorders, congenital and genetic diseases, connective tissue diseases, digestive diseases, ear diseases, nose diseases, throat diseases, endocrine diseases, environmental diseases, eye diseases, female reproductive diseases, fungal infections, heart diseases, hereditary cancer syndromes, immune system diseases, kidney and urinary diseases, lung diseases, male reproductive diseases, metabolic disorders, mouth diseases, musculoskeletal diseases, myelodysplastic syndromes, nervous system diseases, newborn screening, nutritional diseases, parasitic diseases, rare cancers, rare diseases, skin diseases and viral infections; reagent paper for medical purposes; pharmaceutical preparations targeting messenger RNA or other types of RNA, other than for agricultural purposes for the treatment of autoimmune, autoinflammatory diseases, bacterial infections, behavioral and mental disorders, blood diseases, chromosome disorders, congenital and genetic diseases, connective tissue diseases, digestive diseases, ear diseases, nose diseases, throat diseases, endocrine diseases, environmental diseases, eye diseases, female reproductive diseases, fungal infections, heart diseases, hereditary cancer syndromes, immune system diseases, kidney and urinary diseases, lung diseases, male reproductive diseases, metabolic disorders, mouth diseases, musculoskeletal diseases, myelodysplastic syndromes, nervous system diseases, newborn screening, nutritional diseases, parasitic diseases, rare cancers, rare diseases, skin diseases and viral infections; drugs for medical purposes, targeting messenger RNA or other types of RNA for the treatment of autoimmune, autoinflammatory diseases, bacterial infections, behavioral and mental disorders, blood diseases, chromosome disorders, congenital and genetic diseases, connective tissue diseases, digestive diseases, ear diseases, nose diseases, throat diseases, endocrine diseases, environmental diseases, eye diseases, female reproductive diseases, fungal infections, heart diseases, hereditary cancer syndromes, immune system diseases, kidney and urinary diseases, lung diseases, male reproductive diseases, metabolic disorders, mouth diseases, musculoskeletal diseases, myelodysplastic syndromes, nervous system diseases, newborn screening, nutritional diseases, parasitic diseases, rare cancers, rare diseases, skin diseases and viral infections; biological preparations for medical purposes, targeting messenger RNA or other types of RNA for the treatment of autoimmune, autoinflammatory diseases, bacterial infections, behavioral and mental disorders, blood diseases, chromosome disorders, congenital and genetic diseases, connective tissue diseases, digestive diseases, ear diseases, nose diseases, throat diseases, endocrine diseases, environmental diseases, eye diseases, female reproductive diseases, fungal infections, heart diseases, hereditary cancer syndromes, immune system diseases, kidney and urinary diseases, lung diseases, male reproductive diseases, metabolic disorders, mouth diseases, musculoskeletal diseases, myelodysplastic syndromes, nervous system diseases, newborn screening, nutritional diseases, parasitic diseases, rare cancers, rare diseases, skin diseases and viral infections; nucleic acid sequences for medical and veterinary purposes; cells for medical purposes; blood for medical purposes; diagnostic and therapeutic antibodies for medical purposes; vaccines; enzyme inhibitors, only for medical or veterinary purposes; medical assay preparations for therapeutic or diagnostic purposes; medical diagnostic reagents; reagents for medical purposes; reagents for extracting nucleic acids, only for medical or veterinary diagnostic purposes; pharmaceutical preparations containing nucleic acids, targeting messenger RNA or other types of RNA for the treatment of autoimmune, autoinflammatory diseases, bacterial infections, behavioral and mental disorders, blood diseases, chromosome disorders, congenital and genetic diseases, connective tissue diseases, digestive diseases, ear diseases, nose diseases, throat diseases, endocrine diseases, environmental diseases, eye diseases, female reproductive diseases, fungal infections, heart diseases, hereditary cancer syndromes, immune system diseases, kidney and urinary diseases, lung diseases, male reproductive diseases, metabolic disorders, mouth diseases, musculoskeletal diseases, myelodysplastic syndromes, nervous system diseases, newborn screening, nutritional diseases, parasitic diseases, rare cancers, rare diseases, skin diseases and viral infections; reagents for detection, identification, analysis and quantification of nucleic acids for pharmaceutical and diagnostic medical purposes; enzymes for medical purposes; lacteal flour for babies; dietary supplements for humans; dietetic foods in liquid form adapted for medical purposes; dietetic foods adapted for medical purposes; beverages, namely, dietetic foods in the form of liquid for babies; food for babies; dietary supplements for animals

1 Chemicals, namely chemicals for use in medical industry and medical science; small molecule compounds as chemicals for use in medical science and medical industry; nucleic acids for laboratory use excluding the use in industrial chemistry, other than for medical or veterinary purposes; nucleic acid chemical reagents excluding the use in research or development in industrial chemistry, other than for medical or veterinary purposes; reagents and assays for use in scientific, medical or drug discovery research; reagents for chemical analyses, excluding the use in research or development in industrial chemistry, other than for medical or veterinary purposes; reagents for nucleic acid isolation and purification for medical and drug discovery research purposes; reagents for nucleic acid synthesis and analysis for medical and drug discovery research purposes; diagnostic preparations and assay samples for medical and drug discovery research, clinical research, and laboratory use, other than for medical or veterinary purposes; proteins in raw material form and enzymes for scientific and medical research purposes; cells for research or scientific purposes; nucleic acid, namely, DNA deoxyribonucleic acids for laboratory use; nucleic acid, namely, RNA ribonucleic acids for laboratory use; antibodies, namely, antibody reagents for research use, other than for medical or veterinary purposes; artificial sweeteners; raw materials, namely, unprocessed plastics in all forms; none of the foregoing for use in research or development in industrial chemistry

42 Custom design of chemical reagents and biological assays for use in medicines and engineering design services, not for advertising; development of pharmaceutical preparations and medicines; computer software design, computer programming, and maintenance of computer software for use in RNA targeted drug discovery and development; designing, programming and maintenance of computer software having artificial intelligence functionality for use in RNA targeted drug discovery and development; computer software design, computer programming, and maintenance of computer software for use in scientific and technical analysis of data from artificial intelligence for use in RNA targeted drug discovery and development; computer software design, computer programming, and maintenance of computer software for use in analysis, testing, screening, designing, development or research on nucleic acids, pharmaceuticals or chemicals for use in medicines for use in RNA targeted drug discovery and development; computer software design, computer programming, and maintenance of computer software for use in drug discovery screening; computer software design, computer programming, and maintenance of computer software for use in genome research or treatments, pharmaceutical preparations for RNA targeted drug discovery and development; technological advice relating to computers, automobiles and other industrial machines requiring highly specialized knowledge, skills and experiences for proper operation, namely, computer technology consultancy and industrial machine part design consulting for use in RNA targeted drug discovery and development; scientific research, testing and analysis in the field of nucleic acids, pharmaceuticals, drug discovery and development, medicines, chemicals and engineering for use in RNA targeted drug discovery and development; quality control assessment services for use in RNA targeted drug discovery and development for others; testing, inspection or research of pharmaceuticals for use in RNA targeted drug discovery and development; providing information and consultancy on testing, inspection or research of pharmaceuticals, chemicals for use in medicines, reagents for use in medicines for use in RNA targeted drug discovery and development; scientific or laboratory testing, inspection or research of nucleic acids, chemicals and pharmaceuticals for drug development and medical research purposes, and providing scientific information and research consultancy relating thereto for use in RNA targeted drug discovery and development; testing or scientific research on biotechnology and providing scientific information and research consultancy relating thereto for use in RNA targeted drug discovery and development; genomic experiments, analyses, research, assays, tests, inspection, detection or verification, namely, scientific genomic analyses, scientific genomic research, custom design and development of biochemical genomic assays, genome amplification and functional and structural analysis of genomes for use in RNA targeted drug discovery and development; scientific research consultancy, advice and providing scientific research information in the field of genomic experiments, analyses, research, assays, tests, inspection, detection or verification for use in RNA targeted drug discovery and development; scientific and technological services, namely, testing, analysis surveying, research or data analysis in the field of biomedicine, genome biology, pharmacogenomics, diagnostics, clinical trials and bioengineering for use in RNA targeted drug discovery and development; research and development of vaccines and medicines; development of pharmaceutical preparations and medicines; conducting clinical trials for pharmaceuticals for use in RNA targeted drug discovery and development for others; rental of computers; providing computer programs on data networks, namely, providing temporary use of non-downloadable computer software for enabling, supporting and accelerating processes of RNA-targeted drug discovery and development for use in research and development of nucleic acids, pharmaceuticals, medicines and chemicals; providing temporary use of non-downloadable computer software having artificial intelligence functionality on data networks for enabling, supporting and accelerating processes of RNA-targeted drug discovery and development for use in research and development of nucleic acids, pharmaceuticals, medicines and chemicals; providing online non-downloadable computer software for analyzing science and technology data based on artificial intelligence (AI) technology for use in RNA targeted drug discovery and development; providing online non-downloadable computer software for analyzing, testing, screening, designing, developing and researching of nucleic acids, pharmaceuticals and chemicals for use in RNA targeted drug discovery and development; providing online non-downloadable computer software for drug discovery screening; providing online non-downloadable computer software for conducting and accessing genome research and treatments, pharmaceutical preparations for use in RNA targeted drug discovery and development

"IN SILICO"

Trademark Events

Jan 23, 2024

Limitation From The Ib Examined, No Action Is Needed

Nov 25, 2023

Limitation Of Goods Received From Ib

Jan 15, 2023

Final Decision Transaction Processed By Ib

Dec 22, 2022

Final Disposition Notice Sent To Ib

Dec 22, 2022

Final Disposition Processed

Dec 20, 2022

Final Disposition Notice Created, To Be Sent To Ib

Oct 11, 2022

Teas Change Of Correspondence Received

Oct 11, 2022

Teas Change Of Domestic Representatives Address

Oct 11, 2022

Attorney/Dom.Rep.Revoked And/Or Appointed

Oct 11, 2022

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Sep 20, 2022

Notice Of Registration Confirmation Emailed

Sep 20, 2022

Registered-Principal Register

Aug 14, 2022

Extension Of Time To Oppose Process - Terminated

May 25, 2022

Changes/Corrections After Pub Approval Entered

May 24, 2022

Assigned To Petition Staff

May 10, 2022

Teas Post Publication Amendment Received

Apr 28, 2022

Extension Of Time To Oppose Received

Apr 10, 2022

Notification Processed By Ib

Apr 10, 2022

Notification Of Possible Opposition - Processed By Ib

Apr 5, 2022

Official Gazette Publication Confirmation E-Mailed

Apr 5, 2022

Published For Opposition

Mar 23, 2022

Notification Of Possible Opposition Sent To Ib

Mar 23, 2022

Notification Of Possible Opposition Created, To Be Sent To Ib

Mar 16, 2022

Notification Of Possible Opposition Sent To Ib

Mar 16, 2022

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Mar 16, 2022

Notification Of Notice Of Publication E-Mailed

Mar 2, 2022

Letter Of Protest Evidence Reviewed-No Further Action Taken

Feb 8, 2022

Letter Of Protest Evidence Forwarded

Jan 28, 2022

Approved For Pub - Principal Register

Dec 20, 2021

Teas/Email Correspondence Entered

Dec 20, 2021

Correspondence Received In Law Office

Dec 20, 2021

Teas Response To Office Action Received

Jun 24, 2021

Notification Of Non-Final Action E-Mailed

Jun 24, 2021

Non-Final Action E-Mailed

Jun 24, 2021

Non-Final Action Written

May 10, 2021

Teas/Email Correspondence Entered

May 10, 2021

Correspondence Received In Law Office

May 10, 2021

Teas Response To Office Action Received

Nov 29, 2020

Refusal Processed By Ib

Nov 12, 2020

Non-Final Action Mailed - Refusal Sent To Ib

Nov 12, 2020

Refusal Processed By Mpu

Oct 23, 2020

Application Filing Receipt Mailed

Oct 22, 2020

Non-Final Action (Ib Refusal) Prepared For Review

Oct 21, 2020

Non-Final Action Written

Oct 19, 2020

Assigned To Examiner

Oct 19, 2020

New Application Office Supplied Data Entered

Oct 15, 2020

Sn Assigned For Sect 66a Appl From Ib